|Bid||66.95 x 800|
|Ask||72.00 x 1800|
|Day's Range||68.24 - 70.75|
|52 Week Range||36.92 - 72.81|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||52.98|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire
Encouraging service sector figures from Europe and China, along with increasing optimism in U.S.-China trade negotiations ease fears of a global economic downturn.
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ANI Pharmaceuticals, Inc. (ANIP) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
ANI (ANIP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.